SE0102888D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE0102888D0
SE0102888D0 SE0102888A SE0102888A SE0102888D0 SE 0102888 D0 SE0102888 D0 SE 0102888D0 SE 0102888 A SE0102888 A SE 0102888A SE 0102888 A SE0102888 A SE 0102888A SE 0102888 D0 SE0102888 D0 SE 0102888D0
Authority
SE
Sweden
Prior art keywords
dosage form
relates
prevention
active substance
treatment
Prior art date
Application number
SE0102888A
Other languages
Swedish (sv)
Inventor
Karin Ellstroem
Ulf Kjellberg
Haakan Nyquist
Anders Ringberg
Annika Schweighofer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102888A priority Critical patent/SE0102888D0/en
Publication of SE0102888D0 publication Critical patent/SE0102888D0/en
Priority to PCT/SE2002/001542 priority patent/WO2003017984A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a new extended release oral dosage form of the good soluble pharmaceutically active substance, (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide, in the form of the free base or pharmaceutically acceptable salts and/or hydrates or solvates thereof, for use in the prevention and/or treatment of central nervous system (CNS) disorders and related medical disturbances. More particularly, the invention relates to an extended release oral dosage form that provides a defined blood concentration profile having no rapid initial rise in blood plasma concentration of the good soluble active substance when administered at low dose. The invention further relates to processes for preparing said dosage form, the use of said dosage and a method of prevention and/or treatment of CNS disorders and related medical disturbances using said dosage form.
SE0102888A 2001-08-29 2001-08-29 New formulation SE0102888D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0102888A SE0102888D0 (en) 2001-08-29 2001-08-29 New formulation
PCT/SE2002/001542 WO2003017984A1 (en) 2001-08-29 2002-08-28 A new extended release oral dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102888A SE0102888D0 (en) 2001-08-29 2001-08-29 New formulation

Publications (1)

Publication Number Publication Date
SE0102888D0 true SE0102888D0 (en) 2001-08-29

Family

ID=20285179

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102888A SE0102888D0 (en) 2001-08-29 2001-08-29 New formulation

Country Status (2)

Country Link
SE (1) SE0102888D0 (en)
WO (1) WO2003017984A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
CA2652576A1 (en) * 2006-05-19 2007-11-29 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457505B (en) * 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
PE57198A1 (en) * 1996-03-25 1998-10-10 American Home Prod PROLONGED RELEASE FORMULA
SE510305C2 (en) * 1997-05-30 1999-05-10 Astra Ab Fresh salt
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief

Also Published As

Publication number Publication date
WO2003017984A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
NO20065638L (en) Controlled-release formulations containing vardenafil
BR0205722A (en) Prolonged release formulation and method for treating a patient suffering from pain
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE381537T1 (en) FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
DK1256339T3 (en) Transdermal therapeutic system for obtaining high plasma levels of rotigotine in the treatment of Parkinson's disease
IS6970A (en) Solid formulation comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide and PVP
HK1068606A1 (en) Novel aminobenzoephenones
HUP0203716A2 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them
SE0102440D0 (en) New compound
MXPA01008993A (en) Combination treatment for depression and anxiety.
SE0102887D0 (en) New formulation
HUP0300863A2 (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide, process for producing it and pharmaceutical composition containing it
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
SE0102888D0 (en) New formulation
SE9702066D0 (en) A new salt
SE0102886D0 (en) New formulation
TW200502002A (en) A new oral immediated release dosage form
DE60221104D1 (en) SUBSTITUTED DIARYL HARVES AS STIMULATORS OF FAS-MEDIATED APOPTOSIS
HUP0402062A2 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them
HUP0301408A2 (en) Methods and compositions using sulodexide for the treatment of diabetic nephropathy
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
SE0002354D0 (en) New formulation
MX2022006535A (en) Treating behavioral and psychological symptoms in dementia patients.